What would saving 18 months and over $50 million on your lead asset’s development plan mean for your company? For most emerging biotechs, it’s the difference between market leadership and fighting for survival. This isn’t a hypothetical; it’s a real-world example of what’s possible with a truly integrated strategic and operational framework.
The Scenario: An innovative biotech partner, had a promising CAR-T therapy for a rare cancer. Early data was strong, but they faced a daunting challenge: the FDA was open to Accelerated Approval based on response rates, while the EMA made it clear that a full approval would require a randomized, controlled trial with a survival-based endpoint. The default path was two separate, multi-year, nine-figure trials. A path that would have exhausted their resources.
The Strategic Solution: Instead of accepting this flawed path, our cross-functional Hexa-Helix™, uniting regulatory, clinical, and biostatistics experts, designed a single, seamless-adaptive Phase II/III trial. The study began as a single-arm trial to generate the data for a US filing, then seamlessly expanded to include a randomized control arm to generate the robust data required by the EMA, all under one capital-efficient protocol.
The Operational Solution: The immense complexity of CAR-T logistics was managed proactively by our QualityDRIVE™ system. By monitoring Key Risk Indicators (KRIs) for the entire “vein-to-vein” process in real-time, our team was able to intervene to save an irreplaceable cellular product that was delayed in customs. A save that would have been impossible with a traditional, reactive monitoring model.
The outcome of this integrated approach was transformative. By moving beyond siloed thinking to a unified framework, the biotech was positioned to achieve global approval years ahead of schedule and millions of dollars under budget.
These results are the outcome of a deliberate, integrated framework. This level of success is achievable with the right strategic partner.
Download our new White Paper,
“Mastering the Regulatory Gauntlet”, for the complete framework.